Session » Systemic Sclerosis & Related Disorders – Clinical Poster II
- 10:30AM-12:30PM
-
Abstract Number: 1574
Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort
- 10:30AM-12:30PM
-
Abstract Number: 1575
Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1561
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
- 10:30AM-12:30PM
-
Abstract Number: 1578
Association of Systemic Sclerosis and Other Systemic Autoimmune Disease Diagnosis with Increasing Anti-RNA Polymerase III Antibodies
- 10:30AM-12:30PM
-
Abstract Number: 1572
Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1562
Autoantibody Associations with Disease Manifestations in Patients with Early Diffuse Cutaneous Systemic Sclerosis: The Prospective Registry of Early Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1560
Changes of Cerebral Structure and Perfusion Vary in Different Subtypes of Systemic Sclerosis: A Brain Magnetic Resonance Imaging Study
- 10:30AM-12:30PM
-
Abstract Number: 1585
Characterization of the Fecal Metabolome in Early Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1566
Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study
- 10:30AM-12:30PM
-
Abstract Number: 1570
Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung
- 10:30AM-12:30PM
-
Abstract Number: 1568
Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study
- 10:30AM-12:30PM
-
Abstract Number: 1591
Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review
- 10:30AM-12:30PM
-
Abstract Number: 1573
Early Scleroderma with Non-Raynaud’s Symptoms Prior to Raynaud’s Onset Is Associated with Rapid Progression to Diffuse Skin Disease and Joint Contractures
- 10:30AM-12:30PM
-
Abstract Number: 1584
Efficacy of Tofacitinib in the Treatment of Early Diffuse Cutaneous Systemic Sclerosis: A Clinical Study in Bangladesh
- 10:30AM-12:30PM
-
Abstract Number: 1577
Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog
- 10:30AM-12:30PM
-
Abstract Number: 1557
Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1579
Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1571
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1582
Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
- 10:30AM-12:30PM
-
Abstract Number: 1564
Incidence of Posttraumatic Stress Disorder Secondary to the Diagnosis of Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1558
Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry
- 10:30AM-12:30PM
-
Abstract Number: 1590
Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
- 10:30AM-12:30PM
-
Abstract Number: 1581
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
- 10:30AM-12:30PM
-
Abstract Number: 1576
New Patient-Reported Outcome Measures for Early Systemic Sclerosis Using the FDA Guidance on Patient Reported Outcome Measures
- 10:30AM-12:30PM
-
Abstract Number: 1580
Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients
- 10:30AM-12:30PM
-
Abstract Number: 1587
Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort
- 10:30AM-12:30PM
-
Abstract Number: 1565
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
- 10:30AM-12:30PM
-
Abstract Number: 1563
Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma
- 10:30AM-12:30PM
-
Abstract Number: 1569
Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories
- 10:30AM-12:30PM
-
Abstract Number: 1567
Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis
- 10:30AM-12:30PM
-
Abstract Number: 1583
The Association of Weakpositive Anti-RNA Polymerase III Antibodies with the Diagnosis and Complications of Systemic Sclerosis and Other Systemic Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 1586
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 1588
Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
- 10:30AM-12:30PM
-
Abstract Number: 1559
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
- 10:30AM-12:30PM
-
Abstract Number: 1589
Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis